Deltyba – 50mg (DELAMANID)
Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB)
Share Now
Additional Information
| Name | Deltyba |
| Description | The pharmacological mode of action of delamanid involves inhibition of the synthesis of the mycobacterial cell wall components, methoxy-mycolic and keto-mycolic acid. The identified metabolites of delamanid do not show anti-mycobacterial activity. |
| Active Ingredient | Delamanid |
| Indication | Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. |
| Strengths | 50mg |
| Business Partner | Otsuka Novel Products GmbH |
| Origin | Germany |
Related Products
Disclaimer
Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the respective local health authority or contracted by the MAH to supply to the end users on a named patient basis. Some products such as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.
